EKSO BIONICS HOLDING (OTCBB:EKSO) extended its board size to seven by after it elected Amy Wendell to its Board. Wendell used to take care of “Strategy and Business Development” of Covidien plc (NYSE:COV). Nathan Harding, the CEO stated that Wendell strengthens the board as had a successful record in of implementing acquisition plans in her last association.
Ekso Bionics recently made a strong move breaking highs of over $2. It has formed strong base at these levels. The company is one interesting story developing in segment of small caps as it transforms into the top traded stock on OTC exchange. In last trading session, the stock price of EKSO declined 2.03% to close the trading session at $1.93.
There are several reasons to get excited about ESKO. It is an early innovator and operates in the growing industry of bionic exoskeleton. It even intends to apply for up list on reputed exchanges. It has been constantly looking for lucrative associations with key technological firms including a recent deal with Google’s Boston Dynamics to work on a DARPA project.
Since inception, the company has been not linked with any promotional pumps. The stock trades in million as the company has the ability to generate large sums of capital. EKSO Bionics went public via reverse merger in January 2014, simultaneously generating $20.6 million by opting for a bridge debt transaction.
The roller-coaster ride
EKSO started its journey on OTC around $2.50 per share and then surged to $8 before making an all time low of $0.753 in September 2014. IN last trading session, the stock price of EKSO Bionics declined more than 2% to close the trading session at $1.93. The decline came at a share volume of 479,110 compared to share volume of 1 million. The 52-week high of EKSO is $3.53.